



Developing a Successful Grant Fellowship Application: A Primer for Postdocs & Graduate Students

September 24, 2024
3-4:30pm

Nick Giannoukakis, PhD, began his scientific studies at McGill University (Montreal, Canada), receiving his B.Sc. and Ph.D. in 1992 and 1997, respectively. He then went on to complete a postdoctoral fellowship at the University of Pittsburgh School of Medicine in the fields of gene and cell therapy for autoimmune disease and transplantation tolerance. He held the position of Associate Professor of Pathology and Immunology and he was also a member of the Division of Experimental Pathology and the Cellular and Molecular Pathology Graduate Training Program at the University of Pittsburgh School of Medicine. In the summer of 2014, he joined the Allegheny Health Network as part of the newly-created Institute of Cellular Therapeutics where he continued his translational medicine research endeavors in the following major areas: i) Immunomodulation approaches for the treatment of autoimmune disease and transplantation tolerance; ii) Regulatory immune cells; iii) Immunomodulation-based clinical trials for diabetes mellitus (type 1 and type 2). Recently, he joined Teva Pharmaceuticals as a part of the Translational and Precision Medicine Team inside Global Early Clinical R&D in the position of Consultant/Director/Lead of Translational Science and Precision Medicine, Immunology. He retains an academic role as an Adjunct Associate Professor at the University of Pittsburgh School of Medicine where he teaches topics on pancreas and thyroid development and pathology, cell and gene therapy approaches in diabetes mellitus, and immunobiotherapeutics in courses offered by the Department of Pathology and the Department of Immunology. He is also Adjunct Associate Professor in the Department of Biological Sciences at Carnegie Mellon University, where he directs and teaches the Molecular and Cellular Immunology course. He has mentored graduate, MD/PhD students, as well as clinical fellows who have evolved into outstanding clinicians, research scientists and academic faculty in the USA, Europe, and Asia. Dr. Giannoukakis is considered a pioneer in the field of tolerogenic dendritic cell therapy for autoimmunity as he was the first to demonstrate the safety and potential efficacy of these cells in preserving the function of the residual insulin-producing cells of the pancreas in type 1 diabetic patients. He is a primary inventor on a number of patents related to gene, cell, and nanoparticle vaccine therapy for autoimmunity and he is one of the founders of RezQ Bio, a biotechnology entity leveraging dendritic cell and nanoparticle vaccine therapy for autoimmunity. He was a regular member of the NIH NIDDK NRSA F30-F32 Fellowship review panel and the NSF Drug Delivery and Drug Development SBIR review panel (2005-2022).

.